Stocktwits Top 25 Week 17

Our updated list of the market's top stocks.

Stocktwits Top 25 Week 17

Welcome to the Stocktwits Top 25 Newsletter for Week 17 of 2024!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 17:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

S&P 500
ST Top 25 S&P 500

The S&P 500 Top 25 list (+7.53%) outperformed the S&P 500 index (+2.67%).

There were 8 major changes to the list this week.

Check out how the momentum meter has performed vs. the S&P 500 index.

Elevate Your Trading Game 👀

Unleash your trading potential with our new Edge subscription plan—featuring unique social data, an ad-free experience, and more!

The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+6.34%) outperformed the Nasdaq 100 index (+3.99%).

There were 4 major changes to the list this week.

The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+10.98%) outperformed the Russell 2000 index (+2.79%).

There were 4 major changes to the list this week.

Top Dawg Of The Week 🐶

The Top 25 lists' Top Dawg was Cullinan Therapeutics, which rallied 61.56%. 📈

The small-cap biotech company focuses on developing oncology therapies for cancer patients in the U.S. More broadly, the small and mid-cap biotech space remains in focus as investors look for the next “takeover target” big pharma will tap to grow their pipelines. 🕵️

There was no specific news about the stock this week. Instead, the momentum continued following the prior week's news of its strategic expansion into autoimmune diseases and an oversubscribed $280 million private placement. 📰

$CGEM is up 148.28% YTD.

Get In Touch

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Tom Bruni) your feedback; I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 👍

Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍

Join the conversation

or to participate.